Program to Improve Adherence to Breast Cancer Treatment
Pilot Study of a Community Pharmacy-Based Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors
This study is testing a new program to see if it can help women recovering from hormone-sensitive breast cancer stick to their hormone therapy better with support from trained pharmacists.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 66 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CHU de Quebec-Universite Laval Academic / other |
| Locations | 1 site (Québec, Quebec) |
| Trial ID | NCT05887102 on ClinicalTrials.gov |
What this trial studies
This pilot study evaluates the PACHA program, which aims to enhance adherence to adjuvant endocrine therapy (AET) among women recovering from hormone-sensitive breast cancer. The study involves a cluster randomized controlled design where participating community pharmacies are assigned to either a control group or an intervention group that utilizes the PACHA program. Pharmacists in the intervention group receive specialized training and resources to support women in managing their AET. The study assesses the program's feasibility, acceptability, and preliminary effects on treatment adherence.
Who should consider this trial
Good fit: Ideal candidates include women aged 18 and older who have been diagnosed with non-metastatic, hormone-sensitive breast cancer and have started AET within the last six months.
Not a fit: Patients living in residential facilities where AET is not self-managed will not benefit from this program.
Why it matters
Potential benefit: If successful, this program could significantly improve adherence to breast cancer treatment, leading to better health outcomes for survivors.
How similar studies have performed: Other studies have shown promise in using community pharmacy interventions to improve medication adherence, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: For pharmacies : * In the province of Quebec, Canada * At least one pharmacist agrees to take charge of the project in their pharmacy * At least one women has initiated adjuvant endocrine therapy (AET) in the last 6 months in the pharmacy For pharmacists : * Practicing in a pharmacy in the province of Quebec * Provide consent For women : * 18 years old or older * Were diagnosed with a first non-metastatic, hormone-sensitive breast cancer * Received and AET prescription for the first time in the last 6 months * Are fluent in French * Have internet access * Provide consent Exclusion Criteria: For women : • Live in a residential facility where AET is not self-managed
Where this trial is running
Québec, Quebec
- Centre de recherche du CHU de Québec — Québec, Quebec, Canada (Recruiting)
Study contacts
- Study coordinator: Sophie Lauzier, Ph.D.
- Email: sophie.lauzier@crchudequebec.ulaval.ca
- Phone: 418-682-7547
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.